Page last updated: 2024-08-21

quinazolines and Brill-Symmers Disease

quinazolines has been researched along with Brill-Symmers Disease in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	2 (40.00)	2.80

Authors

Authors	Studies
Adib, D; Gupta, D; Mamlouk, K; Nellesen, D; Proudman, D; Yang, J	1
Carlo-Stella, C; Magagnoli, M; Santoro, A	1
Markham, A	1
Eltantawy, A; Evans, K; Sebea, E; Vallejos, X	1

Reviews

4 review(s) available for quinazolines and Brill-Symmers Disease

Article	Year
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3- Advances in therapy, 2022, Volume: 39, Issue:4 Topics: Benzamides; Biphenyl Compounds; Child, Preschool; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Lymphoma, Follicular; Morpholines; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Purines; Pyridones; Pyrimidines; Quinazolines; Quinazolinones; Risk	2022
Copanlisib for the treatment of adults with relapsed follicular lymphoma. Expert review of clinical pharmacology, 2020, Volume: 13, Issue:8 Topics: Administration, Intravenous; Adult; Antineoplastic Agents; Humans; Lymphoma, Follicular; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence	2020
Copanlisib: First Global Approval. Drugs, 2017, Volume: 77, Issue:18 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; Drug Approval; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines; Rituximab; United States; United States Food and Drug Administration	2017
Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma. The Annals of pharmacotherapy, 2019, Volume: 53, Issue:9 Topics: Administration, Intravenous; Aged; Angiogenesis Inhibitors; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence	2019

Other Studies

1 other study(ies) available for quinazolines and Brill-Symmers Disease

Article	Year
Copanlisib (Aliqopa) for relapsed follicular lymphoma. The Medical letter on drugs and therapeutics, 2018, 04-23, Volume: 60, Issue:1545 Topics: Antineoplastic Agents; Drug Costs; Drug Interactions; Humans; Lymphoma, Follicular; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Signal Transduction; Treatment Outcome	2018

Article

Year

Copanlisib (Aliqopa) for relapsed follicular lymphoma.

The Medical letter on drugs and therapeutics, 2018, 04-23, Volume: 60, Issue:1545

Topics: Antineoplastic Agents; Drug Costs; Drug Interactions; Humans; Lymphoma, Follicular; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Signal Transduction; Treatment Outcome

2018